Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 20:11:630780.
doi: 10.3389/fonc.2021.630780. eCollection 2021.

3T DCE-MRI Radiomics Improves Predictive Models of Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

Affiliations

3T DCE-MRI Radiomics Improves Predictive Models of Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

Stefania Montemezzi et al. Front Oncol. .

Abstract

Objectives: To test whether 3T MRI radiomics of breast malignant lesions improves the performance of predictive models of complete response to neoadjuvant chemotherapy when added to other clinical, histological and radiological information.

Methods: Women who consecutively had pre-neoadjuvant chemotherapy (NAC) 3T DCE-MRI between January 2016 and October 2019 were retrospectively included in the study. 18F-FDG PET-CT and histological information obtained through lesion biopsy were also available. All patients underwent surgery and specimens were analyzed. Subjects were divided between complete responders (Pinder class 1i or 1ii) and non-complete responders to NAC. Geometric, first order or textural (higher order) radiomic features were extracted from pre-NAC MRI and feature reduction was performed. Five radiomic features were added to other available information to build predictive models of complete response to NAC using three different classifiers (logistic regression, support vector machines regression and random forest) and exploring the whole set of possible feature selections.

Results: The study population consisted of 20 complete responders and 40 non-complete responders. Models including MRI radiomic features consistently showed better performance compared to combinations of other clinical, histological and radiological information. The AUC (ROC analysis) of predictors that did not include radiomic features reached up to 0.89, while all three classifiers gave AUC higher than 0.90 with the inclusion of radiomic information (range: 0.91-0.98).

Conclusions: Radiomic features extracted from 3T DCE-MRI consistently improved predictive models of complete response to neo-adjuvant chemotherapy. However, further investigation is necessary before this information can be used for clinical decision making.

Keywords: DCE; MRI; breast cancer; machine learning; medical imaging; neoadjuvant chemotherapy; radiomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
LASSO variable selection process. (A) Values of the LASSO regression coefficient as a function of log (Lambda). (B) LOOCV deviance as a function of log (Lambda) and therefore of the number of selected features.
Figure 2
Figure 2
(A) Spearman correlation matrix between real variables and (B) Fisher’s p-values matrix between categorical variables.
Figure 3
Figure 3
Average AUC of the best 6 models as a function of the class of variables (G1, Rad, Hist, NoRad and All) and classifier (RF, random forest; SVR, Support Vector machines Regression; Logit, Logistic regression). Boxplots represent the median value, interquartile range and extremes.
Figure 4
Figure 4
Probability of each variable of being included in a high-performance model, estimated by the frequency with which the variable was selected in one of the 6 best models, as a function of the classifier.

Similar articles

Cited by

References

    1. Schott AF, Hayes DF. Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer. J Clin Oncol (2012) 30:1747–9. 10.1200/JCO.2011.41.3161 - DOI - PubMed
    1. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, et al. . Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated With Neoadjuvant Therapy. J Clin Oncol (2008) 26:246–52. 10.1200/JCO.2007.11.5352 - DOI - PubMed
    1. Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, et al. . Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol (2004) 14:1371–9. 10.1007/s00330-004-2246-z - DOI - PubMed
    1. Pusztai L, Foldi J, Dhawan A, DiGiovanna MP, Mamounas EP. Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers. Lancet Oncol (2019) 20:e390–6. 10.1016/S1470-2045(19)30158-5 - DOI - PubMed
    1. Schmitz AMT, Teixeira SC, Pengel KE, Loo CE, Vogel WV, Wesseling J, et al. . Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes. PloS One (2017) 12:e0176782. 10.1371/journal.pone.0176782 - DOI - PMC - PubMed

LinkOut - more resources